Randomized phase II study of CPT‑11 versus PTX versus each combination chemotherapy with S‑1 for advanced gastric cancer that is refractory to S‑1 or S‑1 plus CDDP: OGSG0701
論文
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201
Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108)
切除不能進行・再発大腸癌に対する後方ラインにおける レゴラフェニブ療法とS-1+ベバシズマブ併用療法の 無作為化比較第Ⅱ相試験(OGSG1301)
Docetaxel plus S‑1 versus cisplatin plus S‑1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS‑3)
Phase II Study of Panitumumab Monotherapy in Chemotherapy- Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer OGSG 1602
A phase II trial of dose‑reduced nab‑paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)
Comparison of S‑1–cisplatin every 5 weeks with capecitabine‑cisplatin every 3 weeks for HER2‑negative gastric cancer (recurrent after S‑1 adjuvant therapy or chemotherapy‑naïve advanced): pooled analysis of HERBIS‑2 (OGSG 1103) and HERBIS‑4A (OGSG 1105) trials
A Phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer
Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer(OGSG0507)